We are pleased to announce the launch of 8 new dual‑stain products, expanding our IHC portfolio for cancer diagnosis.

To meet high clinical demand, we have integrated the p16/Ki‑67 assay with our detection kit into a ready‑to‑use all‑in‑one solution for cervical cancer screening. For lymphoma diagnosis, we offer the EBER/CD3 Dual Stain Kit, combining in situ hybridization and IHC on a single slide. Additionally, our primary antibodies for prostate, breast, and lung cancers are now available individually, offering flexibility and reducing waste.

Featured products include:

1. p16/Ki‑67 Dual Staining Kit – For cervical cancer screening.

A complete kit with matched antibodies and reagents. Visualizing both markers on one slide helps pathologists easily identify problem areas.

• Advantage:Improve the accuracy of CIN grading and assist in the differential diagnosis of difficult cases.

2. EBER/CD3 Dual Staining Kit– For Lymphoma screening.

Detects viral infection and T‑cell phenotype simultaneously, aiding in the diagnosis of complex lymphoma cases.

3. Primary Antibody：AMACR/p63/CKHMW – For Prostate Cancera screening.

The three antibodies can distinguish benign from malignant prostate lesions on a single slide.

• Advantage:Easy color-based reading of basal cell integrity—reduces errors, prevents missed diagnoses, and enables early intervention in precancerous cases.

All products are compatible with manual and automated protocols.It also comes in two setups to fit your experiment: Goat Anti-Mouse HRP / Goat Anti-Rabbit AP, or the other way around.Talent Biomedical delivers flexible, cost‑effective solutions for precise disease diagnosis.

below are the performance of dual-staining for your reference.